Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled
You may also be interested in...
'Alice' In Patent Land: Finding Patentable Digital Health Innovations Is No Easy Task
While the mobile health sector and digital health in general is poised for a major boom, a 2014 case, Alice Corp. v. CLS Bank International, continues to be a major hurdle for manufacturers wanting to patent their software. While there are some recent positive trends, attorneys recommend caution and proactive steps to make the best of the current patent environment.
Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout
Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can be.
Is That A Diagnostic Method Patent Or A Law Of Nature? Supreme Court Hears Arguments
A case argued before the Supreme Court Dec. 7 offers the justices an opportunity to place stricter limits on the types of claims that diagnostic makers can latch onto for patent protection. But while the justices had many questions on appropriate standards for patent eligibility, few clear answers surfaced.